Puleva Biotech S.A.

Caleco Pharma Corp. Announces Entry Into License Agreement With Caleco Pharma Europe S.L.
Marketwire Canada; 11/4/2009; 1320 words; ...of July 31, 2014 to July 30, 2015. Expiration of Puleva Biotech Letter of Intent The Company also reports that its letter of intent dated September 1, 2009 with Puleva Biotech S.A. ("Biotech") has expired. The letter of...

Shareholder Opinions Requested on the Initialization of A Clinical Study involving "Lamiridosin": Review Initiated by Online Financial Magazine and Investor Social Network.
M2 Presswire; 10/14/2009; 1231 words; ...proven track record. After yesterday's news from Caleco Pharma Corp. (OTCBB...announced that, in collaboration with Puleva Biotech S.A., a publicly listed Spanish Corporation...members. We use all of our member's insight when selecting our next investment...

Caleco Pharma Corp. Announces Initiation of Clinical Studies of Lamiridosin (a Dietary Supplement).(Clinical report)
Marketwire Canada; 10/13/2009; 1081 words; ...pleased to announce that, in collaboration with Puleva Biotech S.A. ("Biotech"), a publicly listed Spanish Corporation engaged...Hepatitis C virus and is derived from the Company's proprietary technology that it refers to as the...

Caleco Pharma Corp.-Corporate Update.
Marketwire Canada; 9/30/2009; 910 words; ...have occurred between the Company's management and various corporations...the "Letter of Intent") with Puleva Biotech S.A. ("Biotech"), a publicly...a formal license agreement with Puleva Biotech S.A or that it will be completed...

News and FDA Updates for Pluristem Therapeutics (Nasdaq:PSTI), Targacept (NASDAQ:TRGT), Access Pharmaceuticals (OTC:ACCP), Caleco Pharma (OTC:CAEH).
M2 Presswire; 9/11/2009; 1053 words; ...product, PLX-PAD, the Company's leading product candidate for the treatment...provided an update on the Company's clinical development plan for ProLindac...intent (the "Letter of Intent") with Puleva Biotech S.A. ("Biotech"), a publicly...